High rate of invasive fungal infections after non-T cell depleted haploidentical allo-HSCT even under antifungal prophylaxis

Lien, Ming‐Yu; Yeh, Su‐Peng; Wang, Po‐Nan; Li, Sin-Syue; Dai, Ming‐Shen; Chen, Tsung Chih; Hsieh, Ping‐Yen; Chiou, Lun-Wei; Huang, Wei-Han; Liu, Yi-Chang; Blood, Taiwan; Registry, Marrow Transplantation; Ko, Bor‐Sheng

doi:10.1038/s41409-021-01260-7

Cited by 4 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, we found a significant incidence of IFIs in our mixed but high-risk cohort of patients. The observed rate of 7.6% in this study is in accordance with previously published literature of IFIs in antifungal-naïve population [5][6][7][8][9][10][11][30][31][32][33][34].…”

Section: Discussionsupporting

confidence: 92%

Epidemiology and Antifungal Susceptibility Patterns of Invasive Fungal Infections (IFIs) in India: A Prospective Observational Study

Dabas

Xess

Pandey

et al. 2021

JoF

View full text Add to dashboard Cite

The epidemiology of invasive fungal infections (IFI) is ever evolving. The aim of the present study was to analyze the clinical, microbiological, susceptibility, and outcome data of IFI in Indian patients to identify determinants of infection and 30-day mortality. Proven and probable/putative IFI (defined according to modified European Organization for Research and Treatment of Cancer/Mycoses Study Group and AspICU criteria) from April 2017 to December 2018 were evaluated in a prospective observational study. All recruited patients were antifungal naïve (n = 3300). There were 253 episodes of IFI (7.6%) with 134 (52.9%) proven and 119 (47%) probable/putative infections. There were four major clusters of infection: invasive candidiasis (IC) (n = 53, 20.9%), cryptococcosis (n = 34, 13.4%), invasive aspergillosis (IA) (n = 103, 40.7%), and mucormycosis (n = 62, 24.5%). The significant risk factors were high particulate efficiency air (HEPA) room admission, ICU admission, prolonged exposure to corticosteroids, diabetes mellitus, chronic liver disease (CLD), acquired immunodeficiency syndrome (AIDS), coronary arterial disease (CAD), trauma, and multiorgan involvement (p < 0.5; odds ratio: >1). The all-cause 30-day mortality was 43.4% (n = 110). It varied by fungal group: 52.8% (28/53) in IC, 58.8% (20/34) in cryptococcosis, 39.8% (41/103) in IA, and 33.9% (21/62) in mucormycosis. HEPA room, ICU admission for IC; HEPA rooms, diabetes mellitus for cryptococcosis; hematological malignancies, chronic kidney disease (CKD), sepsis, galactomannan antigen index value ≥1 for IA and nodules; and ground glass opacities on radiology for mucormycosis were significant predictors of death (odds ratio >1). High minimum inhibitory concentration (MIC) values for azoles were observed in C. albicans, C. parapsilosis, C. glabrata, A. fumigatus, A. flavus, R. arrhizus, R. microsporus, and M. circinelloides. For echinocandin, high MIC values were seen in C. tropicalis, C. guillermondii, C. glabrata, and A. fumigatus. This study highlights the shift in epidemiology and also raises concern of high MICs to azoles among our isolates. It warrants regular surveillance, which can provide the local clinically correlated microbiological data to clinicians and which might aid in guiding patient treatment.

show abstract

Section: Discussionsupporting

confidence: 92%

Epidemiology and Antifungal Susceptibility Patterns of Invasive Fungal Infections (IFIs) in India: A Prospective Observational Study

Dabas

Xess

Pandey

et al. 2021

JoF

View full text Add to dashboard Cite

show abstract

“…Recipients of HSCT are at the highest risk of developing fungaemia of all cancer patients in Europe [ 3 ]. The 12-month cumulative incidence of IFD has reached 8 to 10% after allogeneic HSCT, with rates as high as 17% in patients undergoing haploidentical HSCT [ 4 , 5 ]. Immunosuppression with profound and prolonged neutropenia, along with acute graft-versus-host disease (GVHD) are the major factors leading to the increases in susceptibility to fungal infections in this population [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies

Daraškevičius

Petraitis

Davainis

et al. 2022

JoF

View full text Add to dashboard Cite

Invasive fungal diseases (IFD) remain a major cause of morbidity and mortality in hematological patients, especially those undergoing hematopoietic stem cell transplantation (HSCT). Despite relatively high incidence, diagnosis and treatment remain a challenge due to non-specific manifestation and limited antifungal armamentarium. A first-in-class triterpenoid antifungal ibrexafungerp that acts by inhibiting the glucan synthase enzyme in the fungal cell wall was recently approved by the USA Food and Drug Administration for the treatment of vaginal yeast infections. Preclinical data show activity against numerous fungi species, including azole- and echinocandin-resistant strains. Preliminary data from ongoing phase 3 studies in IFD have been encouraging, but the role of ibrexafungerp in hematological patients who develop fungal infections has not yet been described. Herein, we discuss the feasibility of oral ibrexafungerp-based antifungal therapy for adult patients with hematological malignancies who have either undergone HSCT or received treatment with a novel targeted therapy agent. We present four clinical cases where ibrexafungerp alone or in combination with other antifungal agents was successfully employed for the management of refractory fungal infection. We describe real-life experiences showing the potential clinical implementation of ibrexafungerp for patients with hematological malignancies for the first time, and provoke future discussion.

show abstract

Improving Outcomes with Haploidentical Stem Cell Transplantation [HaploSCT] in Children Using Post-transplant Cyclophosphamide: a Single Center Experience

George,

Kulkarni,

Lionel

et al. 2023

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

High rate of invasive fungal infections after non-T cell depleted haploidentical allo-HSCT even under antifungal prophylaxis

Cited by 4 publications

References 12 publications

Epidemiology and Antifungal Susceptibility Patterns of Invasive Fungal Infections (IFIs) in India: A Prospective Observational Study

Epidemiology and Antifungal Susceptibility Patterns of Invasive Fungal Infections (IFIs) in India: A Prospective Observational Study

The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies

Improving Outcomes with Haploidentical Stem Cell Transplantation [HaploSCT] in Children Using Post-transplant Cyclophosphamide: a Single Center Experience

Contact Info

Product

Resources

About